TY  - JOUR
AU  - Pelgrim, Teuntje A. D.
AU  - Philipsen, Alexandra
AU  - Young, Allan H.
AU  - Juruena, Mario
AU  - Jimenez, Ester
AU  - Vieta, Eduard
AU  - Jukić, Marin
AU  - Van der Eycken, Erik
AU  - Heilbronner, Urs
AU  - Moldovan, Ramona
AU  - Kas, Martien J. H.
AU  - Jagesar, Raj R.
AU  - Nöthen, Markus M.
AU  - Hoffmann, Per
AU  - Shomron, Noam
AU  - Kilarski, Laura L
AU  - van Amelsvoort, Thérèse
AU  - Campforts, Bea
AU  - van Westrhenen, Roos
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5548
AB  - (1) Background Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. (2) Methods This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders. A total sample of N = 2500 will be recruited at nine sites in seven countries (expected drop-out rate of 30%). Patients will be randomized to a pharmacogenetic group or a dosing-as-usual group and treated over a 24-week period with four study visits. The primary outcome is personal recovery using the Recovery Assessment Scale as assessed by the patient (RAS-DS), with secondary outcomes including clinical effects (response or symptomatic remission), side effects, general well-being, digital phenotyping, and psychosocial functioning. (3) Conclusions This is, to our knowledge, the first international, multi-center, non-industry-sponsored randomized controlled trial (RCT) that may provide insights into the effectiveness and utility of implementing pharmacogenetic-guided treatment of psychiatric disorders, and as such, results will be incorporated in already available dosing guidelines.
PB  - MDPI
T2  - Pharmaceuticals
T1  - A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study
VL  - 17
IS  - 2
SP  - 151
DO  - 10.3390/ph17020151
ER  - 

@article{
author = "Pelgrim, Teuntje A. D. and Philipsen, Alexandra and Young, Allan H. and Juruena, Mario and Jimenez, Ester and Vieta, Eduard and Jukić, Marin and Van der Eycken, Erik and Heilbronner, Urs and Moldovan, Ramona and Kas, Martien J. H. and Jagesar, Raj R. and Nöthen, Markus M. and Hoffmann, Per and Shomron, Noam and Kilarski, Laura L and van Amelsvoort, Thérèse and Campforts, Bea and van Westrhenen, Roos",
year = "2024",
abstract = "(1) Background Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. (2) Methods This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders. A total sample of N = 2500 will be recruited at nine sites in seven countries (expected drop-out rate of 30%). Patients will be randomized to a pharmacogenetic group or a dosing-as-usual group and treated over a 24-week period with four study visits. The primary outcome is personal recovery using the Recovery Assessment Scale as assessed by the patient (RAS-DS), with secondary outcomes including clinical effects (response or symptomatic remission), side effects, general well-being, digital phenotyping, and psychosocial functioning. (3) Conclusions This is, to our knowledge, the first international, multi-center, non-industry-sponsored randomized controlled trial (RCT) that may provide insights into the effectiveness and utility of implementing pharmacogenetic-guided treatment of psychiatric disorders, and as such, results will be incorporated in already available dosing guidelines.",
publisher = "MDPI",
journal = "Pharmaceuticals",
title = "A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study",
volume = "17",
number = "2",
pages = "151",
doi = "10.3390/ph17020151"
}

Pelgrim, T. A. D., Philipsen, A., Young, A. H., Juruena, M., Jimenez, E., Vieta, E., Jukić, M., Van der Eycken, E., Heilbronner, U., Moldovan, R., Kas, M. J. H., Jagesar, R. R., Nöthen, M. M., Hoffmann, P., Shomron, N., Kilarski, L. L., van Amelsvoort, T., Campforts, B.,& van Westrhenen, R.. (2024). A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study. in Pharmaceuticals
MDPI., 17(2), 151.
https://doi.org/10.3390/ph17020151

Pelgrim TAD, Philipsen A, Young AH, Juruena M, Jimenez E, Vieta E, Jukić M, Van der Eycken E, Heilbronner U, Moldovan R, Kas MJH, Jagesar RR, Nöthen MM, Hoffmann P, Shomron N, Kilarski LL, van Amelsvoort T, Campforts B, van Westrhenen R. A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study. in Pharmaceuticals. 2024;17(2):151.
doi:10.3390/ph17020151 .

Pelgrim, Teuntje A. D., Philipsen, Alexandra, Young, Allan H., Juruena, Mario, Jimenez, Ester, Vieta, Eduard, Jukić, Marin, Van der Eycken, Erik, Heilbronner, Urs, Moldovan, Ramona, Kas, Martien J. H., Jagesar, Raj R., Nöthen, Markus M., Hoffmann, Per, Shomron, Noam, Kilarski, Laura L, van Amelsvoort, Thérèse, Campforts, Bea, van Westrhenen, Roos, "A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study" in Pharmaceuticals, 17, no. 2 (2024):151,
https://doi.org/10.3390/ph17020151 . .

TY  - JOUR
AU  - van Westrhenen, Roos
AU  - Aitchison, Katherine J.
AU  - Ingelman-Sundberg, Magnus
AU  - Jukić, Marin
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3575
AB  - In recent decades, very few new psychiatric drugs have entered the market. Thus, improvement in the use of antidepressant and antipsychotic therapy has to focus mainly on enhanced and more personalized treatment with the currently available drugs. One important aspect of such individualization is emphasizing interindividual differences in genes relevant to treatment, an area that can be termed neuropsychopharmacogenomics. Here, we review previous efforts to identify such critical genetic variants and summarize the results obtained to date. We conclude that most clinically relevant genetic variation is connected to phase I drug metabolism, in particular to genetic polymorphism of CYP2C19 and CYP2D6. To further improve individualized pharmacotherapy, there is a need to take both common and rare relevant mutations into consideration; we discuss the present and future possibilities of using whole genome sequencing to identify patient-specific genetic variation relevant to treatment in psychiatry. Translation of pharmacogenomic knowledge into clinical practice can be considered for specific drugs, but this requires education of clinicians, instructive guidelines, as well as full attention to polypharmacy and other clinically relevant factors. Recent large patient studies (n > 1,000) have replicated previous findings and produced robust evidence warranting the clinical utility of relevant genetic biomarkers. To further judge the clinical and financial benefits of preemptive genotyping in psychiatry, large prospective randomized trials are needed to quantify the value of genetic-based patient stratification in neuropsychopharmacotherapy and to demonstrate the cost-effectiveness of such interventions.
PB  - Frontiers Media S.A.
T2  - Frontiers in Psychiatry
T1  - Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?
VL  - 11
DO  - 10.3389/fpsyt.2020.00094
ER  - 

@article{
author = "van Westrhenen, Roos and Aitchison, Katherine J. and Ingelman-Sundberg, Magnus and Jukić, Marin",
year = "2020",
abstract = "In recent decades, very few new psychiatric drugs have entered the market. Thus, improvement in the use of antidepressant and antipsychotic therapy has to focus mainly on enhanced and more personalized treatment with the currently available drugs. One important aspect of such individualization is emphasizing interindividual differences in genes relevant to treatment, an area that can be termed neuropsychopharmacogenomics. Here, we review previous efforts to identify such critical genetic variants and summarize the results obtained to date. We conclude that most clinically relevant genetic variation is connected to phase I drug metabolism, in particular to genetic polymorphism of CYP2C19 and CYP2D6. To further improve individualized pharmacotherapy, there is a need to take both common and rare relevant mutations into consideration; we discuss the present and future possibilities of using whole genome sequencing to identify patient-specific genetic variation relevant to treatment in psychiatry. Translation of pharmacogenomic knowledge into clinical practice can be considered for specific drugs, but this requires education of clinicians, instructive guidelines, as well as full attention to polypharmacy and other clinically relevant factors. Recent large patient studies (n > 1,000) have replicated previous findings and produced robust evidence warranting the clinical utility of relevant genetic biomarkers. To further judge the clinical and financial benefits of preemptive genotyping in psychiatry, large prospective randomized trials are needed to quantify the value of genetic-based patient stratification in neuropsychopharmacotherapy and to demonstrate the cost-effectiveness of such interventions.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Psychiatry",
title = "Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?",
volume = "11",
doi = "10.3389/fpsyt.2020.00094"
}

van Westrhenen, R., Aitchison, K. J., Ingelman-Sundberg, M.,& Jukić, M.. (2020). Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. in Frontiers in Psychiatry
Frontiers Media S.A.., 11.
https://doi.org/10.3389/fpsyt.2020.00094

van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukić M. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. in Frontiers in Psychiatry. 2020;11.
doi:10.3389/fpsyt.2020.00094 .

van Westrhenen, Roos, Aitchison, Katherine J., Ingelman-Sundberg, Magnus, Jukić, Marin, "Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?" in Frontiers in Psychiatry, 11 (2020),
https://doi.org/10.3389/fpsyt.2020.00094 . .